COMP-Ang1 inhibits apoptosis as well as improves the attenuated osteogenic differentiation of mesenchymal stem cells induced by advanced glycation end products.

[1]  Shee-Eun Lee,et al.  COMP-Ang1, a Variant of Angiopoietin 1, Inhibits Serum-Deprived Apoptosis of Mesenchymal Cells via PI3K/Akt and Mitogen-Activated Protein Kinase Pathways , 2010, Pharmacology.

[2]  K. Jang,et al.  COMP-angiopoietin-1 accelerates bone formation during distraction osteogenesis. , 2010, Bone.

[3]  G. Koh,et al.  COMP-Ang1, a chimeric form of Angiopoietin 1, enhances BMP2-induced osteoblast differentiation and bone formation. , 2010, Bone.

[4]  Yong-ping Su,et al.  More insight into mesenchymal stem cells and their effects inside the body , 2010, Expert opinion on biological therapy.

[5]  S. Yaturu.  Diabetes and skeletal health , 2009, Journal of diabetes.

[6]  K. Alitalo,et al.  Angiopoietin-1 overexpression modulates vascular endothelium to facilitate tumor cell dissemination and metastasis establishment. , 2009, Cancer research.

[7]  R. Prince,et al.  Prevalence and predictors of osteopenia and osteoporosis in adults with Type 1 diabetes , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[8]  Jun Jiang,et al.  Angiopoietin-1 protects mesenchymal stem cells against serum deprivation and hypoxia-induced apoptosis through the PI3K/Akt pathway , 2008, Acta Pharmacologica Sinica.

[9]  Y. Toyama,et al.  Osteoblast-specific Angiopoietin 1 overexpression increases bone mass. , 2007, Biochemical and biophysical research communications.

[10]  D. Graves,et al.  Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. , 2007, Bone.

[11]  D. Graves,et al.  Diabetes enhances mRNA levels of proapoptotic genes and caspase activity, which contribute to impaired healing. , 2006, Diabetes.

[12]  S. Kato,et al.  Advanced Glycation End‐Products Attenuate Human Mesenchymal Stem Cells and Prevent Cognate Differentiation Into Adipose Tissue, Cartilage, and Bone , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  Sung Hyun Kim,et al.  COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Kammerer,et al.  Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Schwartz,et al.  Diabetes Mellitus: Does it Affect Bone? , 2003, Calcified Tissue International.

[16]  D. Barrio,et al.  Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK) , 2003, Molecular and Cellular Biochemistry.

[17]  K. Ozono,et al.  Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[18]  B. L. Roman,et al.  Isolation and expression analysis of three zebrafish angiopoietin genes , 2001, Developmental dynamics : an official publication of the American Association of Anatomists.

[19]  M. Long.  Osteogenesis and bone-marrow-derived cells. , 2001, Blood cells, molecules & diseases.

[20]  D. Vashishth,et al.  Influence of nonenzymatic glycation on biomechanical properties of cortical bone. , 2001, Bone.

[21]  P. Schiller,et al.  Age‐Related Osteogenic Potential of Mesenchymal Stromal Stem Cells from Human Vertebral Bone Marrow , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  K. Kraus,et al.  Mesenchymal stem cells in osteobiology and applied bone regeneration. , 1998, Clinical orthopaedics and related research.

[23]  H. Vlassara.  Recent Progress in Advanced Glycation End Products and Diabetic Complications , 1997, Diabetes.

[24]  N. Kugai,et al.  Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  V. Monnier,et al.  Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. , 1991, The Journal of biological chemistry.

[26]  J. Verhaeghe,et al.  Bone and Mineral Metabolism in BB Rats With Long-Term Diabetes: Decreased Bone Turnover and Osteoporosis , 1990, Diabetes.

[27]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[28]  A. Friedenstein,et al.  Osteogenesis in transplants of bone marrow cells. , 1966, Journal of embryology and experimental morphology.

[29]  A. Tocci,et al.  Mesenchymal stem cell: use and perspectives. , 2003, The hematology journal : the official journal of the European Haematology Association.